Poor pain relief and possible toxicity from high-dose intrathecal opioid treatment: Report of two cases

Anca Popescu, MD, Rajorshi Mitra, MD, Jane Ballantyne, MD, FRCA

Abstract


-

Keywords


-

Full Text:

PDF

References


Winkelmuller M, Winkelmuller W: Long term effects of continuous intrathecal opioid treatment in chronic pain of nonmalignant etiology. J Neurosurg. 1996; 85: 458-467.

Doleys DM, Coleton M, Tutak U: Use of intraspinal infusion therapy with non-cancer pain patients: Follow up and comparison of workers compensation vs. non-workers compensation patients. Neuromodulation. 1998; 1: 149-159.

Roberts LJ, Finch PM, Goucke CR, et al.: Outcome of intrathecal opioids in chronic non-cancer pain. Eur J Pain. 2001; 5(4): 353-361.

Penn RD, Paice JA: Chronic intrathecal morphine for intractable pain. J Neurosurg. 1987; 67: 182-186.

Krames ES, Lanning RM: Intrathecal infusional analgesia for nonmalignant pain: Analgesic efficacy of intrathecal opioid with or without bupivacaine. J Pain Symptom Manage. 1993; 8: 539-548.

Kanoff RB: Intraspinal delivery of opiates by an implantable, programmable pump in patients with chronic, intractable pain of nonmalignant origin. J Am Osteopath Assoc. 1994; 94: 487-493.

Hassenbusch SJ, Stanton-Hicks M, Covington EC, et al.: Longterm intraspinal infusions of opioids in the treatment of neuropathic pain. J Pain Symptom Manage. 1995; 10: 527-543.

Paice JA, Penn RD, Shott S: Intraspinal morphine for chronic pain: A retrospective, multicenter study. J Pain Symptom Manage. 1996; 11: 71-80.

Angel IF, Gould HJ, Carey ME: Intrathecal morphine pump as a treatment option in chronic pain of nonmalignant origin. Surg Neurol. 1998; 49: 92-99.

Tutak U, Doleys DM: Intrathecal infusion systems for treatment of chronic low back and leg pain of noncancer origin. South Med J. 1996; 89: 295-300.

Anderson VC, Burchiel KJ: A prospective study of long-term intrathecal morphine in the management of chronic nonmalignant pain. Neurosurgery. 1999; 44: 289-300.

Kumar K, Kelly M, Pirlo BA: Continuous intrathecal morphine treatment for chronic pain of nonmalignant etiology: long-term benefits and efficacy. Surg Neurol. 2001; 55: 79-88.

Thimineur MA, Kravitz E, Vodapally MS: Intrathecal opioid treatment for chronic non-malignant pain: A 3-year prospective study. Pain. 2004; 109: 242-249.

Schuchard M, Lanning R, North R, et al.: Neurologic sequelae of intraspinal drug delivery systems: Results of a survey of American implanters of implantable drug delivery systems. Neuromodulation. 1998; 1: 137-148.

Hassenbusch SJ, Portenoy RK, Cousins M, et al.: Polyanalgesic consensus conference 2003: An update on the management of pain by intraspinal drug delivery—Report of an expert panel. J Pain Symptom Manage. 2004; 27(6): 540-563.

Ballantyne JC, Mao J: Opioid therapy for chronic pain. N Engl J Med. 2003; 349: 1943-1953.

Portenoy RK, Savage SR: Clinical realities and economic considerations: Special therapeutic issues in intrathecal therapy— Tolerance and addiction. J Pain Symptom Manage. 1997; 14: S27-S35.

Feldberg W, Sherwood SL: Injections of drugs into the lateral ventricle of the cat. J Physiol. 1954; 123: 524-526.

Angst MS, Koppert W, Pahl I, et al.: Short-term infusion of the mu-opioid agonist remifentanil in humans causes hyperalgesia during withdrawal. Pain. 2003; 106(1-2): 49-57.

Hood DD, Curry R, Eisenach JC. Intravenous remifentanil produces withdrawal hyperalgesia in volunteers with capsaicininduced hyperalgesia. Anesth Analg. 2003; 97(3): 810-815.

Guignard B, Bossard AE, Coste C, et al.: Acute opioid tolerance: Intraoperative remifentanil increases postoperative pain and morphine requirement. Anesthesiol. 2000; 93(2): 409-417.

Wagner BK, O’Hara DA: Pharmacokinetics and pharmacodynamics of sedatives and analgesics in the treatment of agitated critically ill patients. Clin Pharmacokinet. 1997; 33(6): 426-453.

Parkinson SK, Bailey SL, Little WL, et al.: Myoclonic seizure activity with chronic high-dose spinal opioid administration. Anesthesiol. 1990; 72: 743-745.

Mao J: Opioid induced abnormal pain sensitivity: Implications in clinical opioid therapy. Pain. 2002; 100: 213-217.

Mao J, Sung B, Ji RR, et al.: Chronic morphine induces down regulation of spinal glutamate transporters: Implications in morphine tolerance and abnormal pain sensitivity. J Neurosci. 2002; 22: 8312-8323.

Mao J, Sung B, Ji RR, et al.: Neuronal apoptosis associated with morphine tolerance: Evidence for an opioid-induced neurotoxic mechanism. J Neurosci. 2002; 22: 7650-7661.

Cicero T: Effects of exogenous and endogenous opiates on the hypothalamic-pituitary-gonadal axis in the male. Fed Proc. 1980; 39(8): 2551-2554.

Genazzani AR, Genazzani AD, Volpogni C, et al.: Opioid control of gonadotrophin secretion in humans. Hum Reprod. 1993; 8(Suppl 2): 151-153.

Jordan D, Tafani JAM, Ries C, et al.: Evidence for multiple opioid receptors in the human posterior pituitary. J Neuroendocrinol. 1996; 8: 883-887.

Veldhuis JD, Rogol AD, Samojlik E, et al.: Role of endogenous opiates in the expression of negative feedback actions of androgen and estrogen on pulsatile properties of luteinizing hormone secretion in man. J Clin Invest. 1984; 74: 47-55.

Cicero TJ, Bell RD, Wiest WG, et al.: Function of the male sex organs in heroin and methadone users. N Engl J Med. 1975; 292(17): 882-887.

Mendelson JH, Mendelson JE, Patch VD: Plasma testosterone levels in heroin addiction and during methadone maintenance. J Pharmacol Exp Ther. 1975; 192: 211-217.

Mendelson JH, Meyer RE, Ellingboe J, et al.: Effects of heroin and methadone on plasma cortisol and testosterone. J Pharmacol Exp Ther. 1975; 195: 296-302.

Daniell HW: Narcotic-induced hypogonadism during therapy for heroin addiction . J Addictive Dis. 2002; 21(4): 47-53.

Fachinetti F, Volpe A, Farci G, et al.: Hypothalamus-pituitary-adrenal axis of heroin addicts. Drug Alcohol Depend. 1985; 15: 361-366.

Khan C, Malik SA, Iqbal MA: Testosterone suppression by heroin. J Pak Med Assoc. 1990; 40(7): 172-173.

Bliesener N, Albrecht S, Schwager A, et al.: Plasma testosterone and sexual function in men on buprenorphine maintenance for opioid dependence. J Clin Endocrinol Metab. 2004; 90(1): 203-206.

Daniell HW: Hypogonadism in men consuming sustainedaction oral opioids. J Pain. 2002; 3(5): 377-384.

Rajagopal A, Vassilopoulou-Sellin R, Palmer JL, et al.: Symptomatic hypogonadism in male survivors of cancer with chronic exposure to opioids. Cancer. 2004; 100(4): 851-858.

Rajagopal A, Vassilopoulou-Sellin R, Palmer JL, et al.: Hypogonadism and sexual dysfunction in male cancer survivors receiving chronic opioid therapy. J Pain Symptom Manage. 2003; 26(5): 1055-1061.

Abs R, Verhelst J, Maeyaert J, et al.: Endocrine consequences of long-term intrathecal administration of opioids. J Clin Endocrinol Metab. 2000; 85(6): 2215-2222.

Finch PM, Roberts LJ, Price L, et al.: Hypogonadism in patients treated with intrathecal morphine. Clin J Pain. 2000; 16(3): 251-254.

Gijbels J, Erdine S, Maeyaert J, et al.: Neuromodulation of pain. A consensus statement of the European Federation of IASP chapters (EFIC). Eur J Pain. 1998; 2: 203-209.

Roberts LJ, Finch PM, Pullan PT, et al.: Sex hormone suppression by intrathecal opioids: A prospective study. Clin J Pain. 2002; 18(3): 144-148.

Daniell HW: The association of endogenous hormone levels and exogenously administered opiates in males. Am J Pain Manage. 2001; 11(1): 8-10.

Pelosi MA, Sama JC, Caterini H, et al.: Galactorrhea-amenorrhea syndrome associated with heroin addiction. Am J Obstet Gynecol. 1974; 118(7): 966-970.

Paice JA, Penn RD: Amenorrhea associated with intraspinal morphine. J Pain Symptom Manage. 1995; 10: 582-583.

Banki CM, Arato M: Multiple hormonal responses to morphine: Relationship to diagnosis and dexamethasone suppression. Psychoneuroendocrinology. 1987; 12: 3-11.

Collu R, Clermont MJ, Ducharme JR: Effects of thyrotrophinreleasing hormone on prolactin, growth hormone and corticosterone secretions in adult male rats treated with pentobarbital or morphine. Eur J Pharmacol. 1976; 37: 133-140.

Lee C, Ludwig S, Duerksen D: Low serum cortisol associated with opioid use—Case report and review of literature. Endocrinologist. 2002; 12(1): 5-8.

Allolio B, Deuss U, Kaulen D, et al.: FK 33-824, a metenkephalin analog, blocks corticotropin-releasing hormoneinduced adrenocorticotropin secretion in normal subjects but not in patients with Cushing’s disease. J Clin Endocrinol Metab. 1986; 63: 1427-1431.

Taylor T, Dluhy RG, Williams GH: Beta-endorphin suppresses adrenocorticotropin and cortisol levels in normal human subjects. J Clin Endocrinol Metab. 1983; 57: 592-596.




DOI: https://doi.org/10.5055/jom.2006.0007

Refbacks

  • There are currently no refbacks.